Paysign (PAYS) 17th Annual Southwest IDEAS Conference summary
Event summary combining transcript, slides, and related documents.
17th Annual Southwest IDEAS Conference summary
20 Nov, 2025Leadership and Industry Expertise
Leadership team and board have deep experience in payments, banking, and healthcare, including former executives from Euronet, Netspend, and Green Dot.
Founder and CEO holds significant ownership, with board members bringing expertise from payments and healthcare banking.
Strategic Direction and Business Overview
Focuses on patient affordability programs, donor compensation, SaaS engagement, and integrated payment processing for life sciences, offering scalable, customizable solutions.
Over 20 years of experience managing all aspects of prepaid card lifecycle in-house, serving major pharmaceutical, healthcare, and multinational clients.
Committed to technology advancements that lower costs, streamline operations, and drive customer revenue.
Business Model and Revenue Streams
Operates in patient affordability and plasma payment sectors, with diverse fee-based revenue including interchange, cardholder, program management, and claims fees.
Patient affordability business is a key growth driver, with recurring monthly fees and per-transaction charges.
Plasma business serves mostly unbanked individuals, generating revenue from card usage and associated fees.
Latest events from Paysign
- Rapid growth in patient affordability and tech-driven margin expansion offset plasma headwinds.PAYS
The MicroCap Rodeo Conference - NYC3 Feb 2026 - Strong revenue growth and market expansion in healthcare-focused prepaid payment solutions.PAYS
Small-Cap Growth Virtual Investor Conference3 Feb 2026 - Q2 revenue up 30% year-over-year, net income positive, and 2024 guidance raised.PAYS
Q2 20242 Feb 2026 - Patient affordability business is rapidly scaling, driving strong growth and margin expansion.PAYS
Sidoti Micro-Cap Virtual Conference2 Feb 2026 - Q3 2024 revenue up 23%, pharma patient affordability revenue up 219% year-over-year.PAYS
Q3 202416 Jan 2026 - 2024 revenue up 23.5%, patient affordability soared 214.5%, 2025 outlook strong.PAYS
Q4 202425 Dec 2025 - Board recommends triennial say-on-pay, all directors up for election, and auditor ratification.PAYS
Proxy Filing1 Dec 2025 - Annual meeting to vote on directors, executive pay, auditor, and say-on-pay frequency.PAYS
Proxy Filing1 Dec 2025 - Record Q2 revenue and profit, driven by pharma growth, margin expansion, and raised guidance.PAYS
Q2 202523 Nov 2025